For the quarter ending 2026-03-31, LGND made $51,722K in revenue. -$13,345K in net income. Net profit margin of -25.80%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues and income | 51,722 | -78,296* | 115,461 | - |
| Cost of captisol | 3,273 | 3,146* | 3,801 | - |
| Amortization of intangibles | 8,097 | 8,417* | 8,097 | - |
| Research and development | 2,148 | 18,125* | 21,019 | - |
| General and administrative | 20,836 | 7,111* | 28,446 | - |
| Financial royalty assets impairment | - | 6,197* | 0 | - |
| Fair value adjustments to partner program derivatives | 0 | -2,499* | 833 | - |
| Total operating costs and expenses | 34,354 | 45,495* | 60,530 | - |
| Gain on sale of pelican | - | 0* | - | - |
| Operating income (loss) | 17,368 | -123,791* | 54,931 | 1,330* |
| Loss (gain) from short-term investments | 3,869 | -4,961* | 7,798 | 92,799* |
| Gain from change in fair value of equity-method investments and other investments | -49,229 | -136,991* | 75,887 | - |
| Interest income | 6,655 | 2,037* | 3,874 | 1,899* |
| Interest expense | 1,747 | 1,985* | 910 | 24* |
| Other non-operating expense, net | -1,175 | 1,240* | -443 | 14,109* |
| Total non-operating expenses, net | -41,627 | -140,660* | 86,206 | 108,783* |
| Gain before income taxes | -24,259 | -264,451* | 141,137 | 110,112* |
| Income tax benefit | -10,914 | -37,085* | 23,864 | 25,519* |
| Net income (gain) from continuing operations | - | -227,366 | - | 84,593 |
| Net loss | -13,345 | -227,366 | 117,273 | 84,593 |
| Basic EPS | -0.67 | -11.905 | 5.99 | 4.592 |
| Diluted EPS | -0.67 | -11.392 | 5.68 | 4.592 |
| Basic Average Shares | 19,883,000 | 19,098,000 | 19,578,000 | 18,423,000 |
| Diluted Average Shares | 19,883,000 | 19,959,000 | 20,629,000 | 18,423,000 |
LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND)